Survodutide (BI 456906): Clinical Overview for Providers

Survodutide, developed under the code BI 456906, is an investigational dual glucagon receptor and GLP-1 receptor agonist in late-stage clinical development for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). It represents the next structural step past the dual incretin approach of tirzepatide — not by adding another incretin, but by adding a counter-regulatory hormone.

This guide situates Survodutide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is survodutide?

Survodutide is a synthetic peptide engineered to activate two receptors at once: the GLP-1 receptor and the glucagon receptor. It is given by weekly subcutaneous injection in trials and is being developed by Boehringer Ingelheim in partnership with Zealand Pharma.

It is investigational. It has not been approved by the FDA for any indication, and it is not available for prescribing outside a clinical trial. Any material offered for sale under this name is not a legitimate pharmaceutical supply.

Why add glucagon?

The inclusion of glucagon agonism looks counterintuitive. Glucagon raises blood glucose, and much of diabetes pharmacology is devoted to suppressing it — GLP-1 agonists themselves work partly by doing so.

The rationale rests on glucagon's other actions. Beyond glycemia, glucagon increases energy expenditure and promotes hepatic fat oxidation. In a dual agonist, the GLP-1 component supplies appetite suppression and reduced intake while offsetting glucagon's hyperglycemic effect, and the glucagon component contributes increased energy output and a direct hepatic action. The intent is to attack body weight from both sides of the energy balance equation rather than intake alone.

That hepatic action is why survodutide is being pursued in MASH as well as obesity. Direct effects on liver fat metabolism are a plausible mechanistic advantage over agents that reduce liver fat mainly as a downstream consequence of weight loss.

What the trial evidence shows

Phase 2 results in obesity were among the more striking reported for any agent at that stage, with mean body weight reductions at the highest doses reaching roughly the high-teens percentage range over approximately 46 weeks, and weight still declining when the trial period ended — suggesting the plateau had not been reached.

A separate phase 2 program in MASH reported improvement in histologic disease activity without worsening of fibrosis, which is the endpoint structure regulators care about in that condition.

Two cautions belong alongside those numbers. Phase 2 results frequently attenuate in larger phase 3 populations, and cross-trial comparisons against semaglutide or tirzepatide are unreliable because the populations, durations, and titration schemes differ. Gastrointestinal adverse effects were dose-related and common, and tolerability at the highest doses is a central question for the phase 3 program.

Regulatory status and patient conversations

Survodutide is not approved. It is in phase 3 development, and results and any regulatory decision remain pending. Nothing about its investigational status permits compounding or sourcing outside a trial.

The practical clinical reality is that patients read the phase 2 headlines and ask about it. The useful answer distinguishes between promising and available: the mechanism is rational, the early data are genuinely notable, and none of that makes it a treatment option today. Patients seeking an approved option now should be directed to the agents that have completed that path. Our peptide formulary tracks the regulatory status of every agent in this category, which moves frequently.